Morning Consult: Drug Pricing Policy Must Prioritize Patients


The drug pricing debate continues to rage on, both at the federal level – look to H.R. 3, seen in the House in 2019 that imported foreign pricing models, which a recent Congressional Budget Office report acknowledges relied on the Quality-Adjusted Life Year to score savings – and in the states, like in my home state of Massachusetts, where our Health Policy Commission has signed a contract with the Institute for Clinical and Economic Review to develop a framework to determine the “value” a drug. What perplexes me about this debate is that though there is messaging about “helping patients,” patients are consulted by policymakers or the press.